Differential expression of peptides serves as an indicator of IgA nephropathy in pediatric patients

CHUNBAO RAO¹², FAN YANG¹, ZHIJUN LAI³, SUJUN CHEN³, XIAOMEI LU² and XIAOYUN JIANG¹

¹Department of Pediatrics, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080; ²Scientific Research Center; ³Pediatric Intensive Care Unit, Children's Hospital of Dongguan, Dongguan, Guangdong 523000, P.R. China

Abstract. Peptide profiles change significantly with aging and peptide biomarkers discovered in adult patients may not be suitable for the evaluation of pediatric patients. The present study was designed to explore alterations in the serum peptidome profile of pediatric patients with IgA nephropathy (IgAN). A total of 17 children diagnosed with IgAN were recruited as the experimental group, 11 sex-matched healthy children were recruited as a healthy control group and 18 sex-matched children with other glomerular diseases were recruited as a disease control group. Serum peptides of each subject were enriched and analyzed by liquid chromatography with tandem mass spectrometry and the subsequently identified IgAN-specific peptides were evaluated using Gene Ontology enrichment and Kyoto Encyclopedia of Genes and Genomes pathway analysis. Subsequently, the function of the IgAN-specific peptides was predicted via sequence comparison with other known functional bioactive peptides. A total of 123 peptides with a fold change ≥2 (P<0.05) and 48 peptides with a fold change >5 (P<0.05) were identified to be differentially expressed between the pediatric IgAN group and the two other groups. Consequently, two putative peptides that may have bioactive effects in the pathogenesis of IgAN in pediatric patients were identified. The serum peptidome profile of pediatric patients with IgAN was significantly different from the disease control group and the healthy control group. These differentially expressed peptides may serve as biomarkers for the minimally invasive diagnosis of pediatric patients with IgAN. Additionally, the potential bioactive peptides specifically expressed in pediatric IgAN patients that were identified in this study may lay a foundation for exploring new therapies for IgAN, such as the creation of novel peptide drugs.

Introduction

IgA nephropathy (IgAN) is one of the most common types of primary glomerular disease worldwide (1). As a chronic progressive disease, 30-50% of patients diagnosed with IgAN ultimately progress to end-stage renal disease (ESRD) (2,3). Therefore, early diagnosis and treatment are crucial to delay or prevent the progression of IgAN to ESRD (4). To date, histopathological diagnosis based on renal biopsy is the only means for the clinical diagnosis and reliable treatment of IgAN (5). However, renal biopsy is an invasive procedure that may give rise to complications, such as pain, fever and perirenal hematoma, and has a number of contraindications, including hypertension, coagulation disorders, atherosclerosis, diabetes and pregnancy (6-9). Furthermore, due to its invasive nature, renal biopsy is difficult to repeat in the same patient during follow-ups; hence, it is not possible to use it to dynamically monitor the effects of treatment. There is therefore a pressing need for minimally invasive, sensitive and specific biomarkers for the early diagnosis of IgAN and the dynamic monitoring of therapeutic effects (10).

Peptidomics is an emerging and potentially promising field for the discovery of clinical biomarkers (11). In the past decade, researchers have shown that patients with IgAN and other glomerular diseases (including acute glomerulonephritis, rapidly progressive glomerulonephritis, chronic glomerulonephritis, asymptomatic hematuria, proteinuria, occult glomerulonephritis and nephrotic syndrome) and healthy controls harbor significantly different peptidome profiles (12-17). They have also discovered certain peptide biomarkers that can distinguish patients with IgAN from healthy controls and patients that have other glomerular diseases with a high degree of sensitivity and specificity. However, all the aforementioned studies were conducted in adult IgAN patients and it has been reported that the peptide profile changes significantly with age (18). Thus, the peptide biomarkers discovered for adult IgAN patients may not be suitable for application to pediatric IgAN patients.

Peptides serve as biomarkers for diagnosis of diseases and some of them are also important bioactive molecules that function as antimicrobials, antioxidants, immunomodulators and angiotensin-converting enzyme inhibitors (ACEIs) (19). The dysregulation of bioactive peptides has been shown to be involved in disease progression (20) and several of these bioactive peptides may prove to be specific targets for novel therapeutics (21).
The present study aimed to characterize the serum peptidome profile of pediatric patients with IgAN. The characterized peptides may serve as potential diagnostic biomarkers or targets of novel drug therapeutics for pediatric IgAN.

Materials and methods

Subject recruitment and sample collection. A total of 17 children (10 males and 7 females; mean age, 8.24±2.44 years; age range, 5-15 years) who were diagnosed with primary IgAN by renal biopsy at the Department of Pediatrics, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China from January 2018 to January 2019. Sun Yat-sen University were recruited. Additionally, 18 patients (11 males and 7 females; mean age, 9.28±2.05 years) with other glomerular diseases, including Henoch-Schonlein purpura nephritis, lupus nephritis and minimal change disease were recruited from the First Affiliated Hospital of Sun Yat-sen University as disease controls. An additional 11 healthy subjects were enrolled from the community clinic, Physical Examination Center, Dongguan Eighth People's Hospital, Dongguan, China (5 males and 6 females; mean age 8.27±2.33 years) were recruited as healthy controls. The profiles of the three groups are summarized in Table 1.

Peripheral blood samples were collected in EDTA coagulation-promoting blood collection tubes, allowed to clot at room temperature for 1 h and then centrifuged at 245 x g for 20 min at room temperature. The resulting serum was transferred to 0.5-ml polypropylene microcentrifuge tubes and stored at -80˚C until ready for use.

The study was approved by The Clinical Research Ethics Committee of The First Affiliated Hospital, Sun Yat-sen University and all the samples were obtained with informed consent from the subjects' guardians.

Peptide extraction. A 500-µl serum sample from each subject was thawed for further peptide extraction. The samples were successively passed through 300-, 30- and 10-kD ultrafiltration centrifuge tubes ( Pall Life Sciences) and the sample (peptide) solutions were collected using filtration membranes by gravity filtration and finally lyophilized. The peptides were dissolved in 600 µl loading buffer. The peptides were then desalted using C18 solid phase extraction cartridges (3 cc/100 mg; Waters Corporation) and lyophilized.

Function study methods of the IgAN-specific peptides. In order to explore the underlying biological functions of IgAN-specific peptides, Gene Ontology (GO) enrichment (www.pathway.com/go/ ) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis (www.kegg.jp) was performed on the precursor proteins. To further uncover the functions of the IgAN-specific peptides, previously reported methods were used (22,23). In summary, the IgAN-specific peptides identified were compared with each known functional peptide present in the BIOPEP database (www. uwm.edu.pl/biochemia/biopep/start_biopep.php) using the BLASTP online tool (https://blast.ncbi.nlm.nih.gov/Blast.cgi?PROGRAM=blastp&PAGE_TYPE=BlastSearch&LINK_LOC=blasthome) (24). The retaining standard used for query sequences was as follows: Identity >50% and E-value <0.5.

Liquid chromatography with tandem mass spectrometry (LC-MS/MS). The lyophilized samples were dissolved in Nano-RPLC buffer A. Peptide solutions were loaded onto a trap column (C18; size, 100 µm x internal diameter, 3 cm; column length, 3 µm; chromatographic packing particle size, 150 Å; chromatographic packing pore size, 10 nmol/l; Suzhou Qiangyao Biological Technology Co., Ltd.) at a flow rate of 2 µl/min and separated on a SPE Supra-Clean™ C18 column (size, 150x4.6 mm; Shenzhen Noyadi Chemical Technology Co., Ltd.) on an Eksigent nanoLC-Ultra™ 2D system (AB SCIEX). Mobile phase A was composed of 2% acetonitrile (ACN) and 0.1% formic acid dissolved in H2O. Mobile phase B was composed of 95% ACN and 0.1% formic acid dissolved in H2O. Mobile phase B was increased by a gradient of 5 to 50% within 70 min. An internal standard for the peptide group was not used in the current study; search parameters were strictly controlled to ensure the accuracy of data. Filter parameter setting were as follows: ±e retention time ±50; feature significance, ±e0; feature fold change, ±1; ±e charge ±10; with peptide ID: True; protein significance, ±e20; protein fold change, ±2; significance method: PEAKSQ; confident unique supports, ≥1; normalization use Total Ion Chromatography; search parameter settings: Quantification type: Label free quantification; mass error tolerance, 20.0 ppm; retention time shift tolerance, 4.0 min; dependent on PID (25): 20; False Discovery Rate threshold, 1%.

A Triple Time-of-flight (TOF) 5600 system combined with a nanoliter spray III ion source (AB SCIEX) was applied using the following parameters: Spray voltage, 2.3 kV; air curtain pressure, 30 psi; atomization pressure, 5 psi; heater temperature, 150˚C. Mass spectrometry scanning was set on information dependent analysis mode and the first-stage TOF-MS single-sheet scan time was 250 msec.

Bioinformatics. The processing, retrieval and analysis of the original .wiff file data collected by mass spectrometry was conducted with Protein Pilot Software 5.0 (AB SCIEX) using the following parameters: No trypsin digestion and no cysteine modification. Variable modifications included deamidation (NQ), oxidation (M), glutamic acid (Pyro-glu), glutamine (Pyro-gln), acetylation (protein N-terminal), maximum variable modification/peptide set to 3 and no fixed posttranslational modifications. The search method was a thorough search analysis: The mass tolerance of mass spectrometry was 20 ppm, mass spectrometry was 0.1 Da, false positive rate was controlled at 1% false discovery rate and protein search unused score >1.3 was regarded as a reliable result. A peptide with confidence >95% was deemed a reliable sequence.

Statistical analysis. To determine the statistical significance between the IgAN group and the healthy control or disease control groups, one-way ANOVA and a post hoc analysis with Bonferroni correction was applied to compare the peptide peak areas. P<0.05 was considered to indicate a statistically significant difference.

Results

Summary of peptides differentially expressed between the IgAN, healthy control and other glomerular disease groups.
The serum peptide profiles of all the 46 participants (characteristics provided in Table I) were analyzed using a Venn diagram (Fig. 1). A total of 4,551 peptides were identified to be differentially expressed between the IgAN group and the healthy control group (Table SI). Among them, 1,173 peptides were significantly differentially expressed (fold change >2; P<0.05; Fig. 1). All the differentially expressed peptides are listed in Table SII. A total of 4,371 peptides were identified to be differentially expressed between the IgAN group and the other glomerular disease group (Table SIII). Among them, 239 peptides were significantly differentially expressed (fold change >2; P<0.05; Fig. 1). All the differentially expressed peptides are listed in Table SIV. Among the 1,173 peptides significantly differentially expressed between the IgAN group and the healthy control group and the 239 peptides significantly differentially expressed between the IgAN group and the other glomerular diseases group, 123 peptides overlapped and were designated as IgAN-specific peptides (Table SV). Of these, 48 peptides had a fold change >5 (P<0.05), including 25 upregulated peptides and 23 downregulated peptides (Table II).

Characteristics of the IgAN-specific peptides. The broad features of the IgAN-specific peptides were analyzed. The molecular weight (MW) of the majority of the peptides ranged from 500-2,000 Da (Fig. 2A) and the isoelectric point (pI) of the majority of peptides ranged from 3.0-6.0 or 8.0-13.0 (Fig. 2B). Fig. 2C demonstrates the distribution of the MW relative to the pI. Of the 123 IgAN-specific peptides, 20 peptides were identified to be proteolytic fragments from 10 precursor proteins (Fig. 2D). The majority of the proteolytic fragments (8 peptides) were derived from fibrinogen α-1 chain (FIBA; P02674) or complement C3 (CO3; P01024; 4 peptides). A total of 4,371 peptides were identified to be differentially expressed between the IgAN group and the other glomerular disease group (Table SIII). Among them, 239 peptides were significantly differentially expressed (fold change >2; P<0.05; Fig. 1). All the differentially expressed peptides are listed in Table SIV. Among these, 48 peptides had a fold change >5 (P<0.05), including 25 upregulated peptides and 23 downregulated peptides (Table II).

Bioinformatics analysis of the precursor proteins of the IgAN-specific peptides. GO enrichment analysis identified ‘induction of bacterial agglutination’, ‘platelet degranulation’, ‘regulation of response to wounding’, ‘blood coagulation’, ‘hemostasis’, ‘coagulation’, ‘regulated exocytosis’ and ‘regulation of heterotypic cell-cell adhesion’.

Table I. Clinical characteristics of the subjects enrolled in the study.

A, IgAN group (n=17)

| No. | Sex | Age (years) | Cr (µmol/l) | U-P (g/24 h) |
|-----|-----|-------------|-------------|--------------|
| 1   | F   | 5           | 38          | 1.58         |
| 2   | M   | 5           | 32          | 0.96         |
| 3   | F   | 8           | 27          | 3.14         |
| 4   | M   | 10          | 51          | 0.21         |
| 5   | F   | 13          | 36          | 2.20         |
| 6   | F   | 9           | 37          | 0.15         |
| 7   | M   | 9           | 44          | 0.32         |
| 8   | F   | 7           | 33          | 0.52         |
| 9   | F   | 10          | 40          | 2.32         |
| 10  | M   | 7           | 38          | 1.54         |
| 11  | F   | 11          | 38          | 3.68         |
| 12  | M   | 7           | 27          | 1.16         |
| 13  | M   | 9           | 69          | 1.35         |
| 14  | M   | 6           | 32          | 1.20         |
| 15  | M   | 4           | 32          | 1.12         |
| 16  | M   | 9           | 49          | 3.28         |
| 17  | M   | 11          | 37          | 0.15         |

B, Healthy control group (n=11)

| No. | Sex | Age (years) | Cr (µmol/l) | U-P (g/24 h) |
|-----|-----|-------------|-------------|--------------|
| 1   | M   | 6           | 55          | 0            |
| 2   | F   | 5           | 68          | 0            |
| 3   | F   | 6           | 59          | 0            |
| 4   | F   | 10          | 78          | 0            |
| 5   | M   | 9           | 33          | 0            |
| 6   | M   | 10          | 74          | 0            |
| 7   | F   | 8           | 82          | 0            |
| 8   | M   | 11          | 37          | 0            |
| 9   | M   | 8           | 65          | 0            |
| 10  | F   | 6           | 77          | 0            |
| 11  | F   | 12          | 71          | 0            |

C, Other glomerular disease group (n=18)

| No. | Sex | Age (years) | Cr (µmol/l) | U-P (g/24 h) |
|-----|-----|-------------|-------------|--------------|
| 1   | M   | 8           | 36          | 1.85         |
| 2   | M   | 6           | 42          | 1.23         |
| 3   | F   | 11          | 40          | 0.54         |
| 4   | M   | 9           | 35          | 0.66         |
| 5   | F   | 7           | 49          | 2.24         |
| 6   | M   | 9           | 40          | 0.45         |
| 7   | F   | 9           | 48          | 1.98         |
| 8   | M   | 5           | 33          | 0.44         |
| 9   | F   | 13          | 40          | 1.78         |
| 10  | M   | 12          | 74          | 0.85         |
| 11  | M   | 11          | 45          | 2.11         |
| 12  | F   | 10          | 38          | 0.54         |

Table I. Continued.

C, Other glomerular disease group (n=18)

| No. | Sex | Age (years) | Cr (µmol/l) | U-P (g/24 h) |
|-----|-----|-------------|-------------|--------------|
| 13  | M   | 8           | 41          | 1.53         |
| 14  | M   | 8           | 40          | 4.72         |
| 15  | F   | 11          | 39          | 0.15         |
| 16  | F   | 10          | 40          | 0.19         |
| 17  | M   | 10          | 31          | 0.20         |
| 18  | M   | 10          | 52          | 0.17         |

F, female; M, male; Cr, serum concentration of creatinine; U-P, protein concentration of urine; IgAN, immunoglobulin A nephropathy.
as biological process-associated terms associated with IgAN-specific peptides (Fig. 3A). With regard to cellular components, ‘secretory granule lumen’, ‘vesicle lumen’, ‘platelet alpha granule lumen’, ‘blood microparticle’, ‘extracellular region’, ‘secretory granule’ and ‘fibrinogen complex’ were among the most highly enriched subcategories (Fig. 3B). Regarding molecular functions, ‘cell adhesion molecule binding’, ‘protein binding’, ‘protein binding, bridging’, ‘binding, bridging’, ‘ubiquitin-like protein ligase activity’, ‘cadherin binding involved in cell-cell adhesion’ and ‘SUMO binding’ were highly enriched subcategories (Fig. 3C). KEGG pathway analysis revealed that the identified peptides were associated with the terms ‘complement and coagulation cascades’, ‘platelet activation’, ‘ubiquitin mediated proteolysis’, ‘legionellosis’, ‘Staphylococcus aureus infection’, ‘leishmaniasis’, ‘pertussis’, ‘protein digestion and absorption’, ‘Chagas disease (American trypanosomiasis)’ and ‘systemic lupus erythematosus’ (Fig. 3D).
Table II. Peptides differentially expressed in IgAN patients with a fold change >5.

| Peptide | MW     | m/z     | IgAN/healthy control Fold change | P-value | IgAN/other glomerular diseases Fold change | P-value |
|---------|--------|---------|----------------------------------|---------|-------------------------------------------|---------|
| A. Upregulated in both comparisons |
| GKSSSYSQFTSSTSYSNYRGDSTFESKSYK MADEAGSEADHEGTHST | 4972.13 | 994.84 | #DIV/0! | 0.0432 | #DIV/0! | 0.0098 |
| TSAGLKLILK | 1043.32 | 522.35 | #DIV/0! | 0.0174 | #DIV/0! | 0.0025 |
| LLLVITGK | 913.17 | 457.32 | #DIV/0! | 0.0099 | 20.83 | 0.0020 |
| CSPDTSGC | 768.81 | 385.13 | #DIV/0! | 0.0413 | 14.98 | 0.0161 |
| FLPLVAMLLV | 1214.62 | 1214.74 | #DIV/0! | 0.0066 | 12.88 | 0.0016 |
| KITHRIWESASLL | 1690.97 | 564.31 | #DIV/0! | 0.0017 | 7.96 | 0.0008 |
| VPPNSNAEEDLPTVELQGVPR | 2531.76 | 844.43 | #DIV/0! | 0.0209 | 10.52 | 0.0086 |
| DSGGQQEAN(+.98)N(+.98)PN(+.98)CCNCI | 1641.66 | 547.85 | #DIV/0! | 0.0000 | 9.99 | 0.0000 |
| IPLDLLLAVPV | 1259.59 | 630.40 | #DIV/0! | 0.0032 | 8.63 | 0.0023 |
| QEKNLPSKETIEQ | 1752.9 | 876.93 | #DIV/0! | 0.0017 | 7.96 | 0.0008 |
| KKKMKSSKK | 1135.5 | 567.38 | #DIV/0! | 0.0017 | 7.96 | 0.0008 |
| LVEGEIAEEAAEKATS | 1646.77 | 823.91 | #DIV/0! | 0.0190 | 7.82 | 0.0019 |
| DDPDAPOQPVTPLQFEG | 1952.15 | 976.48 | #DIV/0! | 0.0017 | 7.96 | 0.0008 |
| EVSETESRQESGIFTNTKESSHHP | 3882.09 | 776.96 | #DIV/0! | 0.0283 | 6.76 | 0.0266 |
| GIAEFPISRG | AFKVPAK | 857.06 | 429.27 | #DIV/0! | 0.0141 | 6.28 | 0.0120 |
| LAALKALAAAG | 1097.37 | 549.36 | #DIV/0! | 0.0074 | 6.09 | 0.0061 |
| MVLKIIAFKP | 1287.71 | 644.41 | #DIV/0! | 0.0003 | 5.93 | 0.0002 |
| LSVLVIAT | 992.22 | 493.81 | #DIV/0! | 0.0032 | 5.87 | 0.0023 |
| Q(-.03)AGAASRMRNFRPGVL | 1614.84 | 807.91 | #DIV/0! | 0.0016 | 5.81 | 0.0015 |
| Q(-.03)EKPSPPSPMPSSTPSPSLNNG | 2208.43 | 736.68 | #DIV/0! | 0.0019 | 5.53 | 0.0033 |
| AEEVHSDPCENNFCNLHGTCAANGT | 2569.79 | 643.00 | #DIV/0! | 0.0018 | 5.17 | 0.0042 |
| KVMRLRKLAP(+.98)QIAN | 1670.04 | 835.51 | 14.60 | 0.0121 | 13.13 | 0.0017 |
| GLQK(+.98)VMAIKSRVLPYLYVPKLT | 3504.32 | 1168.71 | 13.81 | 0.0127 | 7.36 | 0.0040 |
| TPPVNV(+.98)TRVLA | PGGGYGA | 648.67 | 649.29 | 7.16 | 0.0460 | #DIV/0! | 0.0026 |
| RGAASKVKVPM | 1143.41 | 1143.66 | 5.95 | 0.0380 | 11.67 | 0.0032 |

| Peptide | MW     | m/z     | IgAN/healthy control Fold change | P-value | IgAN/other glomerular diseases Fold change | P-value |
|---------|--------|---------|----------------------------------|---------|-------------------------------------------|---------|
| B. Downregulated in both comparisons |
| RTPQIGLLAKTPLSRPK | 2032.46 | 1016.63 | 0.15 | 0.0126 | 0.13 | 0.0390 |
| LQVGIPVA | 795.98 | 796.48 | 0.13 | 0.0128 | 0.10 | 0.0256 |
| GRPGPCADVN | 985.08 | 493.23 | 0.12 | 0.0070 | 0.13 | 0.0224 |
| PRVPKYYV | 858.05 | 858.53 | 0.08 | 0.0453 | 0.17 | 0.0312 |
| LAETLKRKLKVR(+.98)KIESIPVKGIISSKTKQKKEV | 3946.77 | 987.10 | 0.07 | 0.0433 | 0.07 | 0.0390 |
| LRGPHLALEIRLRSLQ(+.98) | 2157.59 | 719.78 | 0.07 | 0.0000 | 0.18 | 0.0472 |
| VGGSY | 481.51 | 482.23 | 0.06 | 0.0000 | 0.16 | 0.0043 |
| VKFSLAVNLAID | 1501.83 | 751.45 | 0.05 | 0.0470 | 0.10 | 0.0465 |
| AIVGIGGGGGGGLLLVIVAVLIAYKRKSR | 2807.51 | 702.43 | 0.04 | 0.0096 | 0.06 | 0.0483 |
| N(+.98)QTLKKGKRENVIRKQREKA | 3475.14 | 869.54 | 0.03 | 0.0030 | 0.02 | 0.0094 |
Identification of potential bioactive peptides associated with IgAN. Consequently, two potential bioactive peptides were identified (Table III). The first peptide was QEKNPLPSKETIEQE, which was upregulated in the IgAN group compared with the BIOPEP database, designated as IgAN-U-P and predicted to have a pro-angiogenic function (26). The second one was
PPVVLAK, which was downregulated in the IgAN group compared with the BIOPEP database, designated as IgAN-D-P and predicted to function as an ACEI.

**Discussion**

In this preliminary prospective study, a pediatric IgAN group, together with age- and gender-matched healthy control and glomerular disease groups were recruited and peptides from their serum samples were enriched by centrifugal ultrafiltration with an accurate MW cutoff, a method used extensively for peptide enrichment via a size-exclusion mechanism (27,28). The serum of each subject was directly analyzed by LC-MS/MS. The results indicated that the serum peptidome profiles of pediatric patients with IgAN were significantly different from those of the healthy control group and those of the other glomerular diseases group. In total, 123 IgAN-specific peptides with fold change >2 and 48 with fold change >5 were identified.

Although there is an urgent need for a minimally invasive and reliable biomarker for the diagnosis of IgAN, the identification of such specific peptides is just the first step in a long process before they can be used in the clinic, which will first require their successful validation. There are a substantial number of urinary peptides that show promise as biomarkers of IgAN; however, all of them require further, rigorous validation in well-planned studies (29). A previous study found 5 peptides that may be candidate serum markers for IgAN and may be associated with the pathogenesis of IgA (30). One of the critical steps in progressing this research into the clinic is the evaluation of these peptides in independent test sets, collected using a multicentric approach (31,32). Additionally, in order to improve accuracy, the mass spectrometry results will be verified in other IgAN patients in a future study.

Although ~60 years have passed since the first description of IgAN in 1968 (33), its exact pathogenesis is largely unknown. A large number of studies have shown that some peptides function as bioactive molecules and are not simply protein degradation products (34). The results of the present study indicated that the upregulated IgAN-specific peptide, QEKNPLPSKETIEQE, may have a pro-angiogenic function. Capillary endothelial cell proliferation is consistently shown to be one of the indicators of the pathological activity of IgAN. Clinically, it is more characteristic of the acute phase and is associated with greater numbers of crescent cells (obtained by performing pathological analyses) compared to cases with no endothelial cell proliferation (35). Hence, capillary endothelial cell proliferation could be considered as a predictor of early disease activity (36). The results of the present study also indicated that the downregulated IgAN-specific peptide, PPVVLAK, may function as an ACEI. Consistently, ACEI agents have been revealed to be a promising therapy for IgAN due to their significant effects on reducing proteinuria (37). Therefore, based on the results of the present study, it is proposed that absence of the pro-angiogenic peptide combined with deficiency of ACEI peptide may be involved in the pathogenesis of IgAN in pediatric patients.

**Acknowledgements**

Not applicable.

**Funding**

The current study was supported by the Dongguan Bureau of Science and Technology for the City Key Program of Science and Technology (grant no. 2016108101038).

**Availability of data and materials**

The datasets used and/or analyzed during the present study are available from the corresponding author on reasonable request.

**Authors' contributions**

ZL conceived and designed the current study and interpreted experimental results. SC, XJ and CR contributed to the design of the study and interpretation of experimental results. XL and FY performed experiments, analyzed data, prepared figures and drafted the manuscript. SC and XJ approved the final version of manuscript. XL and XJ edited and revised the manuscript. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

The current study was approved by The Clinical Research Ethics Committee of The First Affiliated Hospital, Sun Yat-sen University (approval no. 20180706) and all samples were obtained with informed consent.

**Patient consent for publication**

All study participants had given their written informed consent before participating in the study.

---

| Designated name | Sequence | Expression pattern | Known functional peptides | Known activity |
|----------------|----------|--------------------|---------------------------|---------------|
| IgAN-U-P       | QEKNPLPSKETIEQE | Upregulated       | LKLTETQEKNPLPSKETIEQEKQAGES | Pro-angiogenic |
| IgAN-D-P       | PPPVLAK  | Downregulated      | PPPVHL                    | ACEI          |

IgAN, immunoglobulin A nephropathy; ACEI, angiotensin-converting enzyme inhibitor.
Competing interests

The authors declare that they have no competing interests.

References

1. Diniz H, Bandeira M, Teresa A, Besteiro B, Coimbra J, Gomes F and Sampaio S: IgA nephropathy with thrombotic microangiopathy: Is this secondary thrombotic microangiopathy or IgA nephropathy-triggered atypical Hemolytic Uremic Syndrome? Portuguese J Nephrol Hypertension 33: 239-243, 2019.

2. Barratt J and Feehally J: IgA nephropathy. J Am Soc Nephrol 16: 2088-2097, 2005.

3. Smith AC and Feehally J: New insights into the pathogenesis of IgA nephropathy. Pathogenesis of IgA nephropathy. Springer Semin Immunopathol 24: 477-493, 2003.

4. Gallaher JH: IgA nephropathy. Kidney Int 47: 377-387, 1995.

5. Schwartz D and Pullman J: Renal biopsy in pregnancy: Risks, benefits, pathologic findings, and illustrative examples. In: Obstetric and Gynecologic Nephrology. Springer, pp87-90, 2020.

6. Bandari J, Fuller TW, Li RM and D’Agostino LA: Renal biopsy for medical renal disease: Indications and contraindications. Can J Urol 23: 8121-8126, 2016.

7. Summa A, Cervino G and Ozturk S: Primary glomerular diseases in the elderly. World J Nephrol 4: 263-270, 2015.

8. Xu DM, Chen M, Zhou FD and Zhao MH: Risk factors for severe bleeding complications in percutaneous renal biopsy. Am J Med Sci 357: 230-235, 2017.

9. Zhu M, Chen JZ and Xu AP: Factors that can minimize bleeding complications after renal biopsy. Int Urol Nephrol 46: 1969-1975, 2014.

10. Hollis EM: Diffusion-Weighted magnetic resonance imaging in diagnosing graft dysfunction: A non-invasive alternative to renal biopsy. Electron Theses and Dissertations, 2017 https://doi.org/10.18297/etd/2661.

11. Silberring J and Ciborowski P: Biomarker discovery and clinical proteomics. Trends Anal Chem 29: 128, 2010.

12. Graterol F, Navarro-Muñoz M, Ibernón M, López D, Troya MI, Pérez V, Bonet J and Romero R: Poor histological lesions in IgA nephropathy may be reflected in blood and urine peptide profiling. BMC Nephrol 14: 82, 2013.

13. Haubitz M, Wittke S, Weissinger EM, Walden M, Rupprecht HD, Floege J, Haller H and Mischak H: Urine protein patterns can serve as diagnostic tools in patients with IgA nephropathy. Kidney Int 67: 2313-2320, 2005.

14. Julian BA, Wittke S, Novak J, Good DM, Coon JJ, Kellmann M, Zürbign P, Schiffer E, Haubitz M, Moldoveanu Z, et al: Electrophoretic methods for analysis of urine polypeptides in IgA-associated renal diseases. Electrophoresis 28: 4469-4483, 2007.

15. Kaneshiro N, Xiang Y, Nagai K, Kurokawa MS, Okamoto K, Arito M, Masuko K, Yudoh K, Yasuda T, Suematsu N, et al: Comprehensive analysis of short peptides in sera from patients with IgA nephropathy. Rapid Commun Mass Spectrom 23: 3720-3728, 2009.

16. Rocchetti MT, Papale M, d’Apollo AM, Suriano IV, Di Palma AM, Vocino G, Montemurro E, Varlasso R, Grandaliano G, Di Paolo S and Guseludo L: Association of urinary laminin G-like 3 and free K light chains with disease activity and histological injury in IgA nephropathy. Clin J Am Soc Nephrol 8: 1115-1125, 2013.

17. Wu J, Wang N, Wang J, Xie Y, Li Y, Liang T, Wang J, Yin Z, He K and Chen X: Identification of a uromodulin fragment for diagnosis of IgA nephropathy. Rapid Commun Mass Spectrom 24: 1971-1978, 2010.

18. Zurbrig P, Decramer S, Dakna M, Santos J, Good DM, Coon JJ, Bandin F, Mischak H, Bascands JL and Schanstra JP: The human urinary proteome reveals high similarity between kidney aging and chronic kidney disease. Proteomics 9: 2108-2117, 2009.

19. Baumb, Federov M, Eben J, Hoffmann R and Pischetsrieder M: Analysis of the endogenous peptide profile of milk: Identification of 248 mainly casein-derived peptides. J Proteome Res 12: 5447-5462, 2013.

20. Salzman NH, Hung K, Haribhai D, Chu H, Karlsson-Sjoberg J, Amir E, Teggtaz P, Barman M, Hayward M, Eastwood D, et al: Enteric defenses are essential regulators of intestinal microbial ecology. Nat Immunol 11: 76-83, 2010.

21. Buse JB, Sesti G, Schmidt WE, Montanya E, Chang C, Xu Y, Blonde L and Rosenstock J: Lariluglute Effect Action in Diabetes-Study Group: Switching to once-daily lariluglute from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 33: 1300-1303, 2010.

22. Cui X, Li Y, Yang L, You L, Wang X, Shi C, Ji C and Guo X: Peptide analysis of human milk from women delivering macrosomic fetuses reveals multiple means of protection for infants. Oncotarget 7: 63514-63525, 2016.

23. Dallas DC, Guerrero A, Khaldi N, Castillo PA, Martin WF, Smlotowitz JT, Bevins CL, Barile D, German JB and Lebrilla CB: Extensive in vivo human milk peptidemiks reveals specific proteolyis yielding protective antimicrobial peptides. J Proteome Res 12: 2295-2304, 2013.

24. Minkiewicz P, Dziba J, Iwaniaik A, Dziba M and Darewicz M: BIOPEP database and other programs for processing bioactive peptide sequences. J AOAC Int 91: 965-980, 2008.

25. Wang Z, Wang H, Peng Y, Chen F, Zhao L, Li X, Qin J, Li Q, Wang B, Pan B and Guo W: A liquid chromatography-tandem mass spectrometry (LC-MS/MS)-based assay to profile 20 plasma steroids in endocrine disorders. Clin Chim Lab Med 21: 0869, 2020.

26. Dettin G, Ghezzo F, Conconi MT, Urbani L, D’Auria F, Tadiglino C, Guidolin D, Nico B, Ribatti D, Die Bello C and Parignotto PP: In vitro and in vivo pro-angiogenic effects of thymosin-beta4-derived peptides. Cell Immunol 271: 299-307, 2011.

27. Soloviov M and Finch P: Peptidomics: Bridging the gap between proteome and metabolome. Proteomics 6: 744-747, 2006.

28. Srinivasan M and Patel MS: Metabolic programming in the immediate postnatal period. Trends Endocrinol Metab 19: 146-152, 2008.

29. Marek-Bukowiec K, Konieczny A, Ratajczak Y and Witkiewicz W: Candidate urinary peptide biomarkers for IgA nephropathy: Where are we now? Dis Markers 21: 520581, 2018.

30. Ishii E, Okamura J, Tsuchida M, Kobayashi M, Akiyama Y, Nakahata T, Kojima S, Hanada R, Horibe K, Sato T, et al: Infant leukemia in Japan: Clinical and biological analysis of 48 cases. Med Pediatr Oncol 19: 32-31, 1992.

31. Alkalaf A, Zürbign P, Bakker JF, Bilo HJ, Cerna M, Fischer C, Fuchs S, Janssen B, Medek K, Mischak H, et al: Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS One 5: e13421, 2010.

32. Knepper MA: Common sense approaches to urinary biomarker study design. J Am Soc Nephrol 20: 1175-1178, 2009.

33. Berger J and Hinglais N: Intercapillary deposits of IgA-IgG. J Urol (Paris) 74: 694-695, 1966 (In French).

34. Pessione E and Cirrincione S: Bioactive molecules released in olalysis yielding protective antimicrobial peptides. J Proteome Res 12: 2295-2304, 2013.

35. Glassock RJ: IgA nephropathy. Nat Rev Dis Primers 2: 16001, 2016.

36. Grasseck RJ: IgA nephropathy. Nat Rev Dis Primers 2: 16001, 2016.